EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Microglia‐derived Galectin‐9 drives amyloid‐β pathology in Alzheimer's disease

Guoxin Zhang iD, Qinyu Peng, Xiaodi Guo, Lina Pan, Min Xiong, Xingyu Zhang iD, Lijun Dai iD, Zhaohui Zhang, Tingting Xiao, Juanfeng He, Miao Liu, Wei Ke und 1 weitere

Aging Cell · 2025-02 · 24 (2)

DOI: 10.1111/acel.14396 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Aging Cell, 2024-11. Verfasst von Guoxin Zhang und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Renmin Hospital of Wuhan University, Wuhan, China. Hauptthemen laut MEDLINE: Alzheimer Disease, Microglia, Galectins, Amyloid beta-Peptides. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the "New 20 Terms of Universities in Jinan" grant, National Natural Science Foundation of China, the Innovative Research Groups of Hubei Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The accumulation of amyloid‐β (Aβ) and overactivation of microglia contribute to the pathogenesis of Alzheimer's disease (AD), but the interaction between microglial activation and Aβ deposition in AD remains elusive. Here we revealed that Aβ activates microglia and promotes the release of Galectin‐9 (Gal‐9), a member of the β‐galactoside–binding family of lectins. The levels of Gal‐9 in the cerebrospinal fluid and brain tissues of AD patients are higher than those in control subjects. Gal‐9 interacts with Aβ and promotes its aggregation, generating Gal‐9‐Aβ fibrils with enhanced seeding activity and neurotoxicity. The expression of Gal‐9 increases with age in the brains of APP/PS1 transgenic mice. Knockout of Gal‐9 in APP/PS1 mice substantially reduced Aβ sedimentation, neuroinflammation, and cognitive impairment. Moreover, depletion of Gal‐9 inhibited the seeding activity of brain homogenates from APP/PS1 mice. These findings reveal a mechanism by which microglia‐derived Gal‐9 accelerates Aβ aggregation and seeding in AD. Thus, strategies aimed at inhibiting Gal‐9 may hold promise as a disease‐modifying therapy to alleviate AD pathology.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseMicrogliaGalectinsAmyloid beta-PeptidesAnimalsHumansMiceMice, TransgenicMaleDisease Models, AnimalBrain

Stichwörter der Autor:innen

Alzheimer's diseaseamyloid‐βcross‐seedinggalectin‐9neuroinflammation

Substanzen

GalectinsAmyloid beta-PeptidesLGALS9 protein, human

Autor:innen und Institutionen

  • Department of Neurology, Renmin Hospital of Wuhan University, Wuhan, China.
  • TaiKang Center for Life and Medical Sciences, Wuhan University, Wuhan, China.

ORCID-Profile: Guoxin Zhang, Xingyu Zhang, Lijun Dai

Förderung

  • the "New 20 Terms of Universities in Jinan" grant
  • National Natural Science Foundation of China
  • the Innovative Research Groups of Hubei Province
  • the National Key Research and Development Program of China
  • the National Natural Science Foundation of China
  • National Key Research and Development Program of China

Zitieren

APA

Zhang, G., Peng, Q., Guo, X., Pan, L., Xiong, M., Zhang, X., Dai, L., Zhang, Z., Xiao, T., He, J., Liu, M., Ke, W., & Zhang, Z. (2025). Microglia‐derived Galectin‐9 drives amyloid‐β pathology in Alzheimer's disease. Aging Cell, 24(2). https://doi.org/10.1111/acel.14396

Vancouver

Zhang G, Peng Q, Guo X, Pan L, Xiong M, Zhang X, et al. Microglia‐derived Galectin‐9 drives amyloid‐β pathology in Alzheimer's disease. Aging Cell. 2025;24(2). doi:10.1111/acel.14396

BibTeX
@article{Zhang2025,
  author = {Zhang, Guoxin and Peng, Qinyu and Guo, Xiaodi and Pan, Lina and Xiong, Min and Zhang, Xingyu and Dai, Lijun and Zhang, Zhaohui and Xiao, Tingting and He, Juanfeng and Liu, Miao and Ke, Wei and Zhang, Zhentao},
  title = {Microglia‐derived Galectin‐9 drives amyloid‐β pathology in Alzheimer's disease},
  journal = {Aging Cell},
  year = {2025},
  volume = {24},
  number = {2},
  doi = {10.1111/acel.14396}
}
Kostenlos starten →